These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 3344411)

  • 21. [Effect of low doses of oral pamidronate (APD) on the calcemia of osteopenic or osteoporotic patients].
    Roldan EJ; Kerzberg EM; Castelli G; Lloret AP
    Medicina (B Aires); 1996; 56(2):133-7. PubMed ID: 8935564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcaemia of malignancy.
    Morton AR; Cantrill JA; Craig AE; Howell A; Davies M; Anderson DC
    Br Med J (Clin Res Ed); 1988 Mar; 296(6625):811-4. PubMed ID: 3130925
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of disodium dichloromethylene diphosphonate on hypercalcemia produced by bone metastases.
    Chapuy MC; Meunier PJ; Alexandre CM; Vignon EP
    J Clin Invest; 1980 May; 65(5):1243-7. PubMed ID: 6444955
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate.
    Body JJ; Borkowski A; Cleeren A; Bijvoet OL
    J Clin Oncol; 1986 Aug; 4(8):1177-83. PubMed ID: 3016205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical trial on ibandronate in patients with tumor-associated hypercalcemia].
    Wang T; Song ST; Jiang ZF; Bian SG; Wang YJ; Li LQ; Zhu J
    Zhonghua Zhong Liu Za Zhi; 2004 Dec; 26(12):739-41. PubMed ID: 15733393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety of pamidronate in patients with renal failure and hypercalcemia.
    Machado CE; Flombaum CD
    Clin Nephrol; 1996 Mar; 45(3):175-9. PubMed ID: 8706358
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Methylpentylaminopropylidenebisphosphonate (BM 21.0955): a new potent and safe bisphosphonate for the treatment of cancer-associated hypercalcemia.
    Wüster C; Schöter KH; Thiébaud D; Manegold C; Krahl D; Clemens MR; Ghielmini M; Jaeger P; Scharla SH
    Bone Miner; 1993 Aug; 22(2):77-85. PubMed ID: 8251767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose/response study of aminohydroxypropylidene bisphosphonate in tumor-associated hypercalcemia.
    Body JJ; Pot M; Borkowski A; Sculier JP; Klastersky J
    Am J Med; 1987 May; 82(5):957-63. PubMed ID: 3578365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia.
    Gucalp R; Ritch P; Wiernik PH; Sarma PR; Keller A; Richman SP; Tauer K; Neidhart J; Mallette LE; Siegel R
    J Clin Oncol; 1992 Jan; 10(1):134-42. PubMed ID: 1727915
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy.
    Kawada K; Minami H; Okabe K; Watanabe T; Inoue K; Sawamura M; Yagi Y; Sasaki T; Takashima S
    Jpn J Clin Oncol; 2005 Jan; 35(1):28-33. PubMed ID: 15681601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term follow up of breast cancer patients treated for hypercalcaemia with aminohydroxypropylidene bisphosphate (APD).
    Grutters JC; Hermus AR; de Mulder PH; Beex LV
    Breast Cancer Res Treat; 1993; 25(3):277-81. PubMed ID: 8369528
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of a single infusion of alendronate in malignant hypercalcaemia: dose dependency and comparison with clodronate.
    Rizzoli R; Buchs B; Bonjour JP
    Int J Cancer; 1992 Mar; 50(5):706-12. PubMed ID: 1531972
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia.
    Nussbaum SR; Warrell RP; Rude R; Glusman J; Bilezikian JP; Stewart AF; Stepanavage M; Sacco JF; Averbuch SD; Gertz BJ
    J Clin Oncol; 1993 Aug; 11(8):1618-23. PubMed ID: 8336198
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravenous pamidronic acid in hypercalcemia due to parathyroid carcinoma.
    Vega EM; Mautalen CA
    Medicina (B Aires); 1991; 51(2):106-10. PubMed ID: 1820495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single high dose aminohydroxypropylidene diphosphonate infusions to treat cancer-associated hypercalcaemia.
    Cantwell B; Harris AL
    Lancet; 1986 Jan; 1(8473):165-6. PubMed ID: 2867388
    [No Abstract]   [Full Text] [Related]  

  • 36. Phosphate depletion in the rat: effect of bisphosphonates and the calcemic response to PTH.
    Jara A; Lee E; Stauber D; Moatamed F; Felsenfeld AJ; Kleeman CR
    Kidney Int; 1999 Apr; 55(4):1434-43. PubMed ID: 10201008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of the new bisphosphonate ibandronate in the management of bone metastasis following rapid infusion.
    Syrigos KN; Michalaki V; Mitromaras A; Pliarchopoulou F; Katirtzoglou N; Antonaki E; Roussou P
    In Vivo; 2002; 16(5):361-3. PubMed ID: 12494878
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism.
    Jansson S; Tisell LE; Lindstedt G; Lundberg PA
    Surgery; 1991 Sep; 110(3):480-6. PubMed ID: 1845370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Disodium pamidronate (APD) in therapy of hypercalcemia in primary hyperparathyroidism].
    Kotzmann H; Svoboda T; Bernecker P; Clodi M; Woloszczuk W; Niederle B; Waldhäusl W; Luger A
    Wien Klin Wochenschr; 1994; 106(13):422-5. PubMed ID: 8091766
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Simple treatment of tumor-induced hypercalcemia: i.v. aminohydroxypropylidene biphosphonate].
    Portmann L; Häfliger JM; Bill G; Burckhardt P
    Schweiz Med Wochenschr; 1983 Dec; 113(51):1960-3. PubMed ID: 6318306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.